UNCYUnicycive Therapeutics, Inc. insider trades
No insider bought or sold Unicycive Therapeutics, Inc. (UNCY) shares on the open market in the last 90 days. The latest Form 4 transaction on record was filed on Oct 29.
- Market cap
- $104.37M
- as of 2026-10-29
- Latest close
- $3.81
- as of 2026-10-29
- Sector
- Healthcare
- as of 2026-10-29
- Industry
- Biotechnology
- as of 2026-10-29
Cluster
No cluster in the last 90 days under the default rule (14d · ≥2 insiders · all roles).
Form 4 historysince 2024-04-17
Dashed line = amended filing (Form 4/A)
| Insider | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Manning Meredith | Oct 28 | Oct 29 | A · derivative | 3,350 | $0.00 | $0 | 3,350 | No | Form 4 |
| Manning Meredith | Oct 28 | Oct 29 | A · derivative | 27,000 | $3.76 | $101,520 | 27,000 | No | Form 4 |
| Laumas Sandeep | May 14 | Jul 284/A | A · derivative | 47,941 | $0.00 | $0 | 47,941 | No | Form 4/A |
| Kenkare-Mitra Sara | May 14 | Jul 284/A | A · derivative | 47,941 | $0.00 | $0 | 47,941 | No | Form 4/A |
| Jermasek DouglasEVP, Corporate Strategy | May 14 | Jun 154/A | A · derivative | 169,500 | $0.00 | $0 | 169,500 | No | Form 4/A |
| Townsend JohnCFO | May 14 | Jun 154/A | A · derivative | 169,500 | $0.00 | $0 | 169,500 | No | Form 4/A |
| Gupta PramodEVP, Pharmaceuticals and BD | May 14 | Jun 154/A | A · derivative | 169,500 | $0.00 | $0 | 169,500 | No | Form 4/A |
| Gupta Shalabh K.CEO | May 14 | Jun 154/A | A · derivative | 762,200 | $0.00 | $0 | 762,200 | No | Form 4/A |
| Aggarwal Gaurav | Aug 25, 2025 | Aug 26, 2025 | C | 652,900 | not reported | not reported | 1,789,915 | No | Form 4 |
| Aggarwal Gaurav | Aug 25, 2025 | Aug 26, 2025 | D · derivative | 3,199.21 | $1,000.00 | $3,199,210 | not reported | No | Form 4 |
| Jermasek DouglasEVP of Corporate Strategy | Jul 28, 2025 | Jul 30, 2025 | A · derivative | 10,000 | $4.71 | $47,100 | 215,500 | No | Form 4 |
| Gupta PramodEVP, Pharmaceuticals and BD | Jul 28, 2025 | Jul 30, 2025 | A · derivative | 90,000 | $4.71 | $423,900 | 301,986 | No | Form 4 |
| Townsend JohnChief Financial Officer | Jul 28, 2025 | Jul 30, 2025 | A · derivative | 10,000 | $4.71 | $47,100 | 101,557 | No | Form 4 |
| Gupta Shalabh K.CEO | Jul 28, 2025 | Jul 30, 2025 | A · derivative | 325,000 | $4.71 | $1,530,750 | 968,951 | No | Form 4 |
| Kenkare-Mitra Sara | Jul 28, 2025 | Jul 30, 2025 | A · derivative | 21,200 | $4.71 | $99,852 | 39,200 | No | Form 4 |
| Laumas Sandeep | Jul 28, 2025 | Jul 30, 2025 | A · derivative | 21,200 | $4.71 | $99,852 | 41,286 | No | Form 4 |
| Aggarwal Gaurav | Jul 28, 2025 | Jul 30, 2025 | A · derivative | 21,200 | $4.71 | $99,852 | 39,200 | No | Form 4 |
| Aggarwal Gaurav | Feb 18, 2025 | Feb 19, 2025 | C | 1,400,000 | not reported | not reported | 11,370,152 | No | Form 4 |
| Aggarwal Gaurav | Feb 18, 2025 | Feb 19, 2025 | D · derivative | 686 | $1,000.00 | $686,000 | 3,119.21 | No | Form 4 |
| Aggarwal Gaurav | Oct 9, 2024 | Oct 10, 2024 | C | 5,500,000 | not reported | not reported | 9,970,152 | No | Form 4 |
| Aggarwal Gaurav | Oct 9, 2024 | Oct 10, 2024 | D · derivative | 2,695 | $1,000.00 | $2,695,000 | 3,885.21 | No | Form 4 |
| Gupta Shalabh K.CEO | Aug 12, 2024 | Aug 14, 2024 | A · derivative | 232,868 | $0.34 | $79,175 | 6,439,505 | No | Form 4 |
| Jermasek DouglasEVP of Corporate Strategy | Aug 12, 2024 | Aug 14, 2024 | A · derivative | 81,750 | $0.34 | $27,795 | 2,055,000 | No | Form 4 |
| Townsend JohnChief Financial Officer | Aug 12, 2024 | Aug 14, 2024 | A · derivative | 40,256 | $0.34 | $13,687 | 915,565 | No | Form 4 |
| Gupta PramodEVP, Pharmaceuticals and BD | Aug 12, 2024 | Aug 14, 2024 | A · derivative | 81,750 | $0.34 | $27,795 | 2,119,862 | No | Form 4 |
| Gupta Shalabh K.CEO | Apr 15, 2024 | Apr 17, 2024 | A · derivative | 1,319,583 | $1.14 | $1,504,325 | 6,206,637 | No | Form 4 |
| Gupta PramodEVP, Pharmaceuticals and BD | Apr 15, 2024 | Apr 17, 2024 | A · derivative | 463,250 | $1.14 | $528,105 | 2,038,112 | No | Form 4 |
| Jermasek DouglasEVP of Corporate Strategy | Apr 15, 2024 | Apr 17, 2024 | A · derivative | 463,250 | $1.14 | $528,105 | 1,973,250 | No | Form 4 |
| Townsend JohnChief Financial Officer | Apr 15, 2024 | Apr 17, 2024 | A · derivative | 228,119 | $1.14 | $260,056 | 875,309 | No | Form 4 |